Literature DB >> 27164551

Biliary atresia and other cholestatic childhood diseases: Advances and future challenges.

Henkjan J Verkade1, Jorge A Bezerra2, Mark Davenport3, Richard A Schreiber4, Georgina Mieli-Vergani5, Jan B Hulscher6, Ronald J Sokol7, Deirdre A Kelly8, Benno Ure9, Peter F Whitington10, Marianne Samyn5, Claus Petersen9.   

Abstract

Biliary Atresia and other cholestatic childhood diseases are rare conditions affecting the function and/or anatomy along the canalicular-bile duct continuum, characterised by onset of persistent cholestatic jaundice during the neonatal period. Biliary atresia (BA) is the most common among these, but still has an incidence of only 1 in 10-19,000 in Europe and North America. Other diseases such as the genetic conditions, Alagille syndrome (ALGS) and Progressive Familial Intrahepatic Cholestasis (PFIC), are less common. Choledochal malformations are amenable to surgical correction and require a high index of suspicion. The low incidence of such diseases hinder patient-based studies that include large cohorts, while the limited numbers of animal models of disease that recapitulate the spectrum of disease phenotypes hinders both basic research and the development of new treatments. Despite their individual rarity, collectively BA and other cholestatic childhood diseases are the commonest indications for liver transplantation during childhood. Here, we review the recent advances in basic research and clinical progress in these diseases, as well as the research needs. For the various diseases, we formulate current key questions and controversies and identify top priorities to guide future research.
Copyright © 2016 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Alagille syndrome; Biliary atresia; Biliary diversion; Choledochal cyst; Choledochal malformation; Liver transplantation; Progressive familial intrahepatic cholestasis

Mesh:

Year:  2016        PMID: 27164551     DOI: 10.1016/j.jhep.2016.04.032

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  45 in total

Review 1.  The Pediatric Cell Atlas: Defining the Growth Phase of Human Development at Single-Cell Resolution.

Authors:  Deanne M Taylor; Bruce J Aronow; Kai Tan; Kathrin Bernt; Nathan Salomonis; Casey S Greene; Alina Frolova; Sarah E Henrickson; Andrew Wells; Liming Pei; Jyoti K Jaiswal; Jeffrey Whitsett; Kathryn E Hamilton; Sonya A MacParland; Judith Kelsen; Robert O Heuckeroth; S Steven Potter; Laura A Vella; Natalie A Terry; Louis R Ghanem; Benjamin C Kennedy; Ingo Helbig; Kathleen E Sullivan; Leslie Castelo-Soccio; Arnold Kreigstein; Florian Herse; Martijn C Nawijn; Gerard H Koppelman; Melissa Haendel; Nomi L Harris; Jo Lynne Rokita; Yuanchao Zhang; Aviv Regev; Orit Rozenblatt-Rosen; Jennifer E Rood; Timothy L Tickle; Roser Vento-Tormo; Saif Alimohamed; Monkol Lek; Jessica C Mar; Kathleen M Loomes; David M Barrett; Prech Uapinyoying; Alan H Beggs; Pankaj B Agrawal; Yi-Wen Chen; Amanda B Muir; Lana X Garmire; Scott B Snapper; Javad Nazarian; Steven H Seeholzer; Hossein Fazelinia; Larry N Singh; Robert B Faryabi; Pichai Raman; Noor Dawany; Hongbo Michael Xie; Batsal Devkota; Sharon J Diskin; Stewart A Anderson; Eric F Rappaport; William Peranteau; Kathryn A Wikenheiser-Brokamp; Sarah Teichmann; Douglas Wallace; Tao Peng; Yang-Yang Ding; Man S Kim; Yi Xing; Sek Won Kong; Carsten G Bönnemann; Kenneth D Mandl; Peter S White
Journal:  Dev Cell       Date:  2019-03-28       Impact factor: 12.270

2.  Non-invasive urinary metabolomic profiles discriminate biliary atresia from infantile hepatitis syndrome.

Authors:  Wei-Wei Li; Yan Yang; Qi-Gang Dai; Li-Li Lin; Tong Xie; Li-Li He; Jia-Lei Tao; Jin-Jun Shan; Shou-Chuan Wang
Journal:  Metabolomics       Date:  2018-06-21       Impact factor: 4.290

Review 3.  Biliary atresia: unity in diversity.

Authors:  Claus Petersen
Journal:  Pediatr Surg Int       Date:  2017-10-05       Impact factor: 1.827

4.  Regulation of bile duct epithelial injury by hepatic CD71+ erythroid cells.

Authors:  Li Yang; Pranavkumar Shivakumar; Jeremy Kinder; Sing Sing Way; Bryan Donnelly; Reena Mourya; Zhenhua Luo; Jorge A Bezerra
Journal:  JCI Insight       Date:  2020-06-04

5.  Association of polymorphism in the VEGFA gene 3'-UTR +936T/C with susceptibility to biliary atresia in a Southern Chinese Han population.

Authors:  Fei Liu; Jixiao Zeng; Deli Zhu; Ruizhong Zhang; Xiaogang Xu; Mengmeng Wang; Yan Zhang; Huimin Xia; Zhichun Feng
Journal:  J Clin Lab Anal       Date:  2017-12-18       Impact factor: 2.352

Review 6.  Clinical phenotype and molecular analysis of a homozygous ABCB11 mutation responsible for progressive infantile cholestasis.

Authors:  Kazuo Imagawa; Hisamitsu Hayashi; Yusuke Sabu; Ken Tanikawa; Jun Fujishiro; Daigo Kajikawa; Hiroki Wada; Toyoichiro Kudo; Masayoshi Kage; Hiroyuki Kusuhara; Ryo Sumazaki
Journal:  J Hum Genet       Date:  2018-03-05       Impact factor: 3.172

7.  Cytokine-Producing B Cells Promote Immune-Mediated Bile Duct Injury in Murine Biliary Atresia.

Authors:  Joseph Bednarek; Brianna Traxinger; Dania Brigham; Jonathan Roach; David Orlicky; Dong Wang; Roberta Pelanda; Cara L Mack
Journal:  Hepatology       Date:  2018-07-10       Impact factor: 17.425

8.  Nasobiliary drainage prior to surgical biliary diversion in progressive familial intrahepatic cholestasis type II.

Authors:  Giulia Jannone; Xavier Stephenne; Isabelle Scheers; Françoise Smets; Catherine de Magnée; Raymond Reding; Etienne M Sokal
Journal:  Eur J Pediatr       Date:  2020-04-14       Impact factor: 3.183

Review 9.  Recent developments in diagnostics and treatment of neonatal cholestasis.

Authors:  Amy G Feldman; Ronald J Sokol
Journal:  Semin Pediatr Surg       Date:  2020-07-23       Impact factor: 2.754

Review 10.  Biliary Atresia: Clinical and Research Challenges for the Twenty-First Century.

Authors:  Jorge A Bezerra; Rebecca G Wells; Cara L Mack; Saul J Karpen; Jay H Hoofnagle; Edward Doo; Ronald J Sokol
Journal:  Hepatology       Date:  2018-09       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.